Ranbaxy to demerge drug discovery operation
Ranbaxy Laboratories Ltd has informed about the following:
- R&D De-merger for Drug Discovery Research (DDR)
Ranbaxy received an in-principle approval from the Board to de-merge its Drug Discovery Research operation. The Company believes that this is a significant step in creating an independent pathway for DDR with dedicated resources and enhanced focus for long-term value building. Ranbaxy has state of the art Research infrastructure and a highly skilled scientific talent pool. These strengths can be more effectively leveraged through an independent vehicle that better aligns assets with priorities to accelerate the Company’s drug discovery programmes. The resulting operational freedom and flexibility will also help to open up new growth opportunities while providing a platform for increased collaboration. The specific framework and other details of the de-merger will be finalized by the end of the year.
